influenza virus vaccine + pneumococcal vaccine

This intervention refers to the co-administration of a seasonal influenza virus vaccine and a 23-valent polyvalent pneumococcal vaccine, specifically as utilized in clinical research conducted by the National Institute of Allergy and Infectious Diseases (NIAID). In the clinical trial NCT00001080, these vaccines were used as immunological probes to induce transient immune activation in HIV-1 infected individuals. The goal was to determine if the resulting T-cell activation would trigger the release of HIV-1 from latent reservoirs or increase the pool of cells susceptible to viral replication, thereby affecting the turnover of lamivudine-sensitive and resistant viral strains. While both vaccines are standard prophylactic agents—the influenza vaccine targeting viral hemagglutinin and neuraminidase, and the pneumococcal vaccine targeting Streptococcus pneumoniae capsular polysaccharides—their use in this context was mechanistic rather than purely preventative.

Other names

Influenza Virus VaccinePneumococcal Vaccine Polyvalent (23-valent)influenza virus vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-influenza-pneumococcal infection